GleamWall
中文EN

SKYE Skye Bioscience, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1516551 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY26.5%
TTM EPS YoY126.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-220.3%
ROA-162.4%
ROIC (approx.)-557.6%
Asset turnover—

Leverage & solvency

Liabilities / assets73.2%
Debt / equity0.00x
Current ratio1.36x
Interest coverage-4,388.42x

Cash quality & payout

Operating cash flow / net income0.81x
Accruals ratio-30.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$42.36M$18.70M$5.82M$6.01M$2.93M
SG&A expense$15.80M$17.73M$7.85M$6.09M$4.92M
Operating income-$58.16M-$30.19M-$34.74M-$18.31M-$7.85M
Interest expense$0$749,308$906,270$665,133$769,159
Pretax income-$55.92M-$26.56M-$37.64M-$19.47M-$8.52M
Income tax$5,400$10,071$3,600$6,741$2,100
Net income-$55.92M-$26.57M-$37.64M-$19.48M-$8.52M
EBITDA-$57.44M-$29.89M-$34.61M-$18.20M-$7.81M
EPS (basic)-1.41-0.73-5.37-8.77-0.02
EPS (diluted)-1.41-0.73-5.37-8.77-0.02
Weighted avg. shares (diluted)39.66M36.49M7.01M2.22M406.60M
Balance sheet
Cash & equivalents$5.88M$68.42M$10.34M$1.25M$8.99M
Short-term investments$19.85M$0———
Current assets$27.09M$70.83M$11.65M$8.94M$9.61M
PP&E, net$898,930$1.43M$43,276$87,854$87,710
Total assets$28.31M$72.76M$11.94M$9.11M$9.86M
Current liabilities$8.21M$4.34M$13.90M$12.12M$3.91M
Total liabilities$8.29M$4.61M$14.07M$12.12M$3.99M
Shareholders' equity$20.02M$68.15M-$2.13M-$3.01M$5.86M
Shares outstanding4.17M30.97M12.35M3.65M476.11M
Cash flow statement
Operating cash flow-$43.06M-$25.24M-$13.95M-$12.74M-$6.47M
Capital expenditure$6,312$1.60M$12,550$28,060$90,866
Free cash flow-$43.07M-$26.84M-$13.96M-$12.77M-$6.57M
Investing cash flow-$19.50M-$245,615$6.60M$5.21M-$90,866
Financing cash flow$29,571$83.56M$16.44M-$208,794$13.08M
Depreciation & amortization$723,352$298,640$124,251$114,998$34,131
Stock-based compensation$7.77M$8.32M$987,510$629,032$869,206

Free plan shows the latest 5 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-19 06:28.